# Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Source: https://onco.cc/trials/nct06087653/  
OnCo record `nct06087653` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Lenalidomide, Dexamethasone in multiple myeloma, run by Starton Therapeutics, Inc, now recruiting.

## Summary

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06087653 by Starton Therapeutics, Inc, with 24 participants planned, started 2023-10-02 and due to reach its primary completion in 2027-05-31. Interventions recorded: Lenalidomide, Lenalidomide 25 MG Oral Capsule. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06087653
- Phase: 1/2
- Setting: A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration of Low-dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma (MM)
- Sponsor: Starton Therapeutics, Inc
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06087653: https://clinicaltrials.gov/study/NCT06087653

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)

---
JSON: https://onco.cc/api/v1/entities/nct06087653.json